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tIn little more than a decade, evidence-based
edicine has evolved from a theoretical—and often
ontroversial—concept into a widely practiced
ethodology that can enhance the critical processes
f medical decision making. Fears that evidence-
ased medicine would elevate the science at the
xpense of the art of medicine and handcuff physi-
ians to rigid “one size ﬁts all” practice guidelines
ave diminished. A thorough, systematic evidence-
ased review is a powerful tool to assist physicians
nd patients who otherwise must make choices on
he basis of conventional wisdom, hearsay, and
iecemeal empirical data.
We have learned much since 1999, when the
merican Society for Blood and Marrow Trans-
lantation (ASBMT) launched its initiative to con-
uct evidence-based reviews of blood and marrow
ransplantation in the treatment of selected dis-
ases. Often, the process has been as valuable for
hat it cannot tell us as for what it can. A systematic
eview may reveal a preponderance of conﬂicting
tudies or conclude that there simply is not enough
mpirical evidence to support one recommendation
ver another. By taking a hard look at the quality a
B&MTnd quantity of the science, evidence-based medi-
ine often highlights the gaps in our science and
alidates the art that every good physician brings to
linical practice—an art based on a synergistic blend
f empirical knowledge, clinical experience, and hu-
an intuition.
We also have learned that the art of medicine has
role in the review process itself. In practice, review-
rs often must grapple with numerous variables that
re difﬁcult to quantify objectively yet affect the qual-
ty and strength of the evidence. In response, the
tandards of evidence-based medicine have evolved
eyond grading schema that rank evidence on strictly
bjective criteria. Although these objective measure-
ents remain important, the Society’s ﬁrst evidence-
ased reviews for diffuse large-cell B-cell lymphoma
DLCL) [1] and multiple myeloma (MM) [2] taught us
ot to rely on study design alone to deﬁne the best
vidence. To do so can undermine optimal patient
are, such as when a study is compromised by poor
ethodology or inappropriate interpretation of re-
ults. There were some instances, for example, when
he independent experts who served on the DLCL
nd MM panels unanimously agreed to discount some
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8f the randomized controlled trials (RCTs) because, in
he end, they did not sufﬁciently answer the questions
osed.
HANGING CRITERIA FOR ASBMT REVIEWS
The original methodology called for a periodic
ssessment of the process of conducting the reviews
3]. In response to an evaluation of the ﬁrst 2 reviews,
he ASBMT Steering Committee for Evidence-Based
eviews in 2004 adopted the following changes in
riteria for conducting future reviews.
ocus of Reviews
The evidence-based reviews conducted by the
SBMT thus far (DLCL, MM, and acute lympho-
lastic leukemia [ALL]) have considered all relevant
spects of transplantation for each disease state within
single review article. For future topics, the Steering
ommittee will establish the initial focus for each
eview and develop a list of questions to be addressed.
his approach not only shortens the review process,
ut also, more importantly, allows us to focus on the
uestions that are most relevant to today’s clinicians
nd scientists.
nclusion Criteria
In past reviews, inclusion criteria for evidence
ere largely determined by each expert panel. For
uture reviews, the Steering Committee has estab-
ished 4 standard criteria:
. Meeting abstracts and data from non–peer-reviewed
journals will be excluded.
. Only evidence from studies published in 1990 or later
will be included.
. A minimum of 70% of study subjects must be patients
with the disease under review, or study results must be
stratiﬁed by the disease to be included.
. Studies with fewer than 25 patients will be excluded,
unless they will affect treatment recommendations (eg,
where no large studies exist or where they are ﬂawed by
problems in design, methodology, or reporting of results).
ethodology
The methodology for the ASBMT-sponsored re-
iews was established in 1999 according to well-ac-
epted standards for evidence-based medicine. In
pril 2001, the US Agency for Healthcare Research
nd Quality sponsored a study of the methods used for
ystematic reviews. The agency published a critical
valuation of the established schemas for grading the
uality and strength of the evidence and reviewed the
0 it determined to be of the highest quality. After
eviewing the systems recommended by the Agency
or Healthcare Research and Quality, the Steering
ommittee selected a grading schema for future re- g
20iews based on guidelines developed by the Scottish
ntercollegiate Guidelines Network (SIGN) of the
oyal College of Physicians of Edinburgh [4].
The SIGN criteria most closely resemble the orig-
nal grading criteria for the ASBMT reviews yet also
ddress a deﬁciency of our prior grading schema: the
ack of an assessment of quality for individual studies
ithin each category of study design. To evaluate
ethodologic quality, SIGN uses standardized check-
ists of criteria to rate studies as follows:
 All or most criteria from the checklist are ful-
ﬁlled or, when not fulﬁlled or adequately de-
scribed, are judged to be highly unlikely to alter
the study’s conclusions.
Some of the criteria from the checklist are ful-
ﬁlled; where not fulﬁlled or adequately de-
scribed, they are unlikely to alter conclusions.
Few or no criteria are fulﬁlled, and those not
fulﬁlled or adequately described are very likely
or likely to alter conclusions.
More information about SIGN, including the
criteria checklists for rating methodologic qual-
ity, can be found at http://www.sign.ac.uk/
guidelines/fulltext/50/.
alidating the System
An unanswered question about SIGN was whether
he methodology for quality assessment was sufﬁ-
iently objective to facilitate consistent, unbiased ap-
lication of the grading criteria by multiple raters.
efore formally adopting the new system for the
SBMT reviews, the Steering Committee undertook
n interrater reliability study to validate the SIGN
ethodology.
Of the approximately 180 scientiﬁc articles ini-
ially selected for inclusion in the ALL review, approx-
mately 10% (n  18) were randomly chosen by a
hird party. Four members of the ASBMT Steering
ommittee acted as raters of these studies and were
sked to rank each article according to the SIGN
hecklist and rating system. The consensus rating
mong the 4 raters was signiﬁcantly consistent: 44%
f the time, the raters had perfect agreement; 33% of
he time, 1 rater differed; 17% of the time, the raters
ere split evenly; and only 6% of the time, there was
o consensus between raters (P  .0001; Pearson
xact 2). The  statistic can be used only to compare
nterrater agreement between 2 raters; therefore, the
earson exact 2 was used to compare the consistency
f grading among the 4 raters.
OW SIGN ENHANCES THE ASBMT REVIEW PROCESS
The SIGN criteria are comparable to those that
overned the ASBMT’s ﬁrst 2 reviews, and their ap-
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Evolution of the Evidence-Based Review
Blication, in the Committee’s opinion, will not change
r invalidate the consensus recommendations reached
y the expert panels that conducted the DLCL and
M evidence-based reviews. At the same time, the
ew schema advances the process by:
Giving due weight to methodologic variables
within a study’s design that can signiﬁcantly affect
the quality of evidence or affect the study’s appli-
cability to a given patient population.
Presenting a more thorough overall picture of the
entire body of available evidence and avoiding the
pitfall of overreliance on the conclusions of single
studies or types of studies.
The SIGN system also preserves the strengths of
ur earlier review criteria. The hierarchy of study
ypes recommended by the Agency for Healthcare
esearch and Quality and widely accepted by experts
emains the ﬁrst step in grading the quality of design
nd strength of the evidence.
EVELS OF EVIDENCE
 High-quality meta-analyses, systematic re-
views of RCTs, or RCTs with a very low risk
of bias.
 Well-conducted meta-analyses, systematic re-
views of RCTs, or RCTs with a low risk of
bias.
 Meta-analyses, systematic reviews of RCTs, or
RCTs with a high risk of bias.
 High-quality systematic reviews of case-con-
trol or cohort studies; high-quality case-con-
trol or cohort studies with a very low risk of
confounding, bias, or chance and a high prob-
ability that the relationship is causal.
 Well-conducted case-control or cohort studies
with a low risk of confounding, bias, or chance
and a moderate probability that the relation-
ship is causal.
 Case-control or cohort studies with a high risk
of confounding, bias, or chance and a signiﬁ-
cant risk that the relationship is not causal.
Nonanalytic studies, eg, case reports or case
series.
Expert opinion.
YNTHESIS OF THE EVIDENCE
After the evidence has been assembled and rated
ccording to the hierarchy of the study design and the
uality of the methodology, relevant data are ab-
tracted from studies that meet the inclusion criteria
or the review. Relevant data from the individual stud-
es are summarized in text format, and tables summa-
izing information about study quality (eg, sample size
nd duration of follow-up) also are created to facilitate b
B&MTxpert assessment of the overall direction and weight
f the evidence.
ONSIDERED JUDGMENT
Once the evidence has been synthesized according
o rigorous objective standards, the art of medicine
omes into play as members of the expert panels begin
he process of making and grading the strength of
heir recommendations. Here, the experts’ individual
nowledge and clinical experience are drawn upon as
hey consider the evidence—or lack of evidence—to
nswer the questions posed by the review. To reduce
he risk of introducing personal bias into the review,
his step relies on the consensus of many individuals
ho are experts in myriad aspects of the disease under
nvestigation. The expert panel convened to conduct
he evidence-based review of ALL, for example, com-
rises nationally recognized authorities in both pedi-
tric and adult ALL, including those who specialize in
ransplantation and those whose expertise is in other
reatment modalities for the disease.
RADES OF RECOMMENDATION
The treatment recommendations of the expert
anel also are subject to a standardized grading sys-
em.
At least 1 meta-analysis, systematic review, or
RCT rated as 1 and directly applicable to the
target population or a systematic review of RCTs
or a body of evidence consisting principally of
studies rated as 1, directly applicable to the tar-
get population, and demonstrating overall consis-
tency of results.
A body of evidence including studies rated as
2, directly applicable to the target population,
and demonstrating overall consistency of results
or extrapolated evidence from studies rated as
1 or 1.
A body of evidence including studies rated as 2,
directly applicable to the target population, and
demonstrating overall consistency of results or
extrapolated evidence from studies rated as 2.
Evidence level 3 or 4 or extrapolated evidence
from studies rated as 2.
MPLICATIONS FOR PAST AND FUTURE REVIEWS
The SIGN system was adopted for the Society’s
vidence-based reviews of ALL in children and adults,
hich respectively appear in this issue and the January
006 issue of this journal, and will be the standard for
ubsequent ASBMT reviews. The new system also will
e applied to the completed reviews on DLCL and
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8M when they are updated as new evidence becomes
vailable.
It is our belief that the new system will enhance
he Society’s evidence-based review process by ad-
ressing the following:
The many areas of medical science in which ran-
domized trials may not be practical or ethical.
Concerns that the controlled, randomized trial,
although widely accepted as the most robust study
design with the least risk of bias to answer ques-
tions of effectiveness, may not always be the best
evidence to answer other questions or that it may
have methodologic ﬂaws that undermine its
strength.
Interpretations of studies that overgeneralize re-
sults, thus contributing to misleading expecta-
tions about efﬁcacy.
The limitations of guidelines that grade the
strength but not the importance of the evidence;
this may result in user confusion and discourage
consideration of some low-grade yet signiﬁcant
recommendations [4].
With this modiﬁcation in the system for conduct-
ng the reviews, the Society signals its commitment to
he highest current standards of evidence-based med-
cine. The more thorough and unbiased the review,
he more it meets our objective to support patients
nd providers in the complicated process of choosing
reatment options.At its best, evidence-based medicine advances its
22eld of inquiry and points toward research that will
ead to better diagnostic and treatment options. Pan-
lists for the ASBMT evidence- based reviews identify
reas where there is insufﬁcient evidence to support
reatment recommendations and prioritize the ques-
ions that, in their expert opinion, are most important
o answer through future research.
As the science of evidence-based medicine evolves,
he ASBMT review process also will evolve to keep
ace with advances. The ultimate goal, however, re-
ains unchanged: to give every patient access to the
reatment option that offers the best chance for sur-
ival and a high quality of life.
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